Anbio Biotechnology has launched its Chikungunya IgM/IgG Rapid Test to aid in the swift diagnosis of Chikungunya fever, a mosquito-borne disease prevalent in tropical and subtropical areas.
The test helps healthcare professionals in distinguishing Chikungunya from other arboviral infections like Dengue and Zika, enhancing public health responses to outbreaks.
It employs immunochromatographic technology for detecting Chikungunya-specific antibodies in human samples, reinforcing Anbio’s infectious disease diagnostics offerings.
In addition, Anbio has launched the AP-100 Ultra-Fast PCR system, which facilitates laboratory-grade testing at the point of care
The system leverages a microfluidic thermal cycling system for efficient sample processing.
The AP-100 system delivers results in fifteen minutes without nucleic acid extraction, using a compact device suitable for mobile testing.
It covers a range of pathogens, including COVID-19 and influenza, and offers lab-comparable accuracy.
Anbio plans to expand its assay portfolio to include tuberculosis and human papillomavirus tests, aiming for comprehensive disease management.
Anbio Biotechnology CEO Michael Lau said: “Outbreaks demand speed. The AP-100 collapses hours of traditional PCR into minutes, without compromising accuracy.
“Whether it’s vector-borne fevers or respiratory pandemics, we believe diagnostics should move as fast as the threat.”
Anbio Biotechnology is a Germany-based in vitro diagnostics company offering solutions like immunofluorescence and molecular diagnostics.
The company offers timely diagnostics to support healthcare decision-making worldwide.
Earlier this year, Anbio launched its Dry Chemiluminescence Immunoassay (CLIA) Solution ADL-1000, designed to deliver rapid, reliable, and cost-effective diagnostic results.
The solution, customised for diverse clinical settings, meets the growing demand for streamlined workflows and high-performance testing.
